Summary:
A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous ly2127399 in patients with Systemic Lupus Erythematosus (SLE).
Qualified Participants Must:
• Not have had an active infection in the last 30 days
•
Not have a serious infection or blood-clotting event within 90/180 days respectively
Qualified Participants May Receive:
Up to $388 paid for compensation plus all study related tests and treatment are at no cost.